Agreements reached under this partnership
Business alliance- 1
Jointly file a substance patent application for a new drug candidate substance targeting lncRNA H19
- 2
Develop ASO manufacturing methods and processes in parallel with drug discovery research
- 3
Create a nucleic acid drug with high activity and low toxicity that can achieve quality, reliability and an appropriate cost in commercial manufacturing
- 4
Aim to establish manufacturing methods at an early stage and advance rapidly to clinical trials
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Research and development expenditures for the year ending December 2026 have been incorporated into the earnings forecast announced on 12 February 2026, and no changes to that forecast are expected.
| Item | Details |
|---|---|
| Name of alliance partner | Mitsubishi Gas Chemical Company, Inc. |
| Alliance partner's business activities | Provision of nucleic acid drug substance CRDMO services (AXELPHEX) |
| Type of alliance | Business alliance |
| Details of the alliance | Jointly file a substance patent application for a new drug candidate substance targeting lncRNA H19, Develop ASO manufacturing methods and processes in parallel with drug discovery research, Create a nucleic acid drug with high activity and low toxicity that can achieve quality, reliability and an appropriate cost in commercial manufacturing, Aim to establish manufacturing methods at an early stage and advance rapidly to clinical trials |
| Contract Date | 3 July 2025 |
| Impact on Business Performance | Research and development expenditures for the year ending December 2026 have been incorporated into the earnings forecast announced on 12 February 2026, and no changes to that forecast are expected. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The progress of the joint research demonstrated that lncRNA can be targeted using our technology, and led to the successful creation of a new drug candidate substance. This patent application represents the achievement of the KPI for fiscal 2026, the creation of an in-house pipeline.